Literature DB >> 28337819

PAI-1 in granulosa cells is suppressed directly by statin and indirectly by suppressing TGF-β and TNF-α in mononuclear cells by insulin-sensitizing drugs.

Kaori Yamada-Nomoto1, Osamu Yoshino1, Ikumi Akiyama2, Akira Iwase3, Yosuke Ono1, Tomoko Nakamura3, Miyuki Harada2, Akitoshi Nakashima1, Tomoko Shima1, Akemi Ushijima1, Yutaka Osuga2, Russell Jeffrey Chang4, Shunichi Shimasaki4, Shigeru Saito1.   

Abstract

PROBLEM: Plasminogen activator inhibitor-1 (PAI-1) is elevated in women with polycystic ovary syndrome (PCOS), but the regulation in granulosa cells (GCs) is unclear. METHOD OF STUDY: PAI-1 expression in PCOS ovaries was investigated immunohistologically. PAI-1 expressions in HGrC1, a human GC cell line, were investigated at mRNA and activity levels. The expressions of TGF-β and TNF-α in peritoneal fluid mononuclear cells (PFMCs) were measured with quantitative PCR.
RESULTS: Little PAI-1 expression is observed in healthy GCs, whereas GCs of PCOS and atretic follicle exhibit distinct expression in vivo. In vitro study using HGrC1 shows that TGF-β and TNF-α increase PAI-1 mRNA and its activity, and both together exhibit a synergistic effect. The expression of PAI-1 mRNA is suppressed by simvastatin. Moreover, insulin-sensitizing drugs (metformin, pioglitazone, and rosiglitazone) suppress LPS-induced TGF-β and TNF-α mRNA expression in PFMC.
CONCLUSION: Statin and insulin-sensitizing drugs may provide a potential therapy for PCOS via down-regulation of PAI-1 expression in GCs and down-regulation of TGF-β and TNF-α expression in PFMC, respectively.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  PAI-1; granulosa cell; polycystic ovary syndrome; statin

Mesh:

Substances:

Year:  2017        PMID: 28337819      PMCID: PMC5468471          DOI: 10.1111/aji.12669

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  30 in total

1.  A macrophage activation marker chitotriosidase in women with PCOS: does low-grade chronic inflammation in PCOS relate to PCOS itself or obesity?

Authors:  Ibrahim Alanbay; Cihangir Mutlu Ercan; Mehmet Sakinci; Hakan Coksuer; Mustafa Ozturk; Serkan Tapan
Journal:  Arch Gynecol Obstet       Date:  2012-06-21       Impact factor: 2.344

2.  Establishment of a human nonluteinized granulosa cell line that transitions from the gonadotropin-independent to the gonadotropin-dependent status.

Authors:  Akira Iwase; Tohru Kiyono; Sachiko Takikawa; Maki Goto; Tomoko Nakamura; Yoshinari Nagatomo; Tatsuo Nakahara; Tomomi Kotani; Hiroharu Kobayashi; Mika Kondo; Shuichi Manabe; Fumitaka Kikkawa
Journal:  Endocrinology       Date:  2012-03-30       Impact factor: 4.736

3.  Elevated interleukin-16 levels in the peritoneal fluid of women with endometriosis may be a mechanism for inflammatory reactions associated with endometriosis.

Authors:  Kaori Koga; Yutaka Osuga; Osamu Yoshino; Yasushi Hirota; Tetsu Yano; Osamu Tsutsumi; Yuji Taketani
Journal:  Fertil Steril       Date:  2005-04       Impact factor: 7.329

4.  Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.

Authors:  L Gao; F-L Zhao; S-C Li
Journal:  Exp Clin Endocrinol Diabetes       Date:  2012-05-25       Impact factor: 2.949

5.  Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis.

Authors:  Osamu Yoshino; Yutaka Osuga; Yasushi Hirota; Kaori Koga; Tetsuya Hirata; Miyuki Harada; Chieko Morimoto; Tetsu Yano; Osamu Nishii; Osamu Tsutsumi; Yuji Taketani
Journal:  Am J Reprod Immunol       Date:  2004-11       Impact factor: 3.886

Review 6.  The role of TGF-β in polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Margrit Urbanek; Raymond J Rodgers; Richard S Legro
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

Review 7.  Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins.

Authors:  Brenda R Kwak; Flore Mulhaupt; François Mach
Journal:  Autoimmun Rev       Date:  2003-10       Impact factor: 9.754

8.  Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

Authors:  Long Wang; Jason Rockwood; Danielle Zak; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Metab Syndr Relat Disord       Date:  2008-06       Impact factor: 1.894

9.  Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice.

Authors:  Jessica K Devin; Joyce E Johnson; Mesut Eren; Linda A Gleaves; William S Bradham; John R Bloodworth; Douglas E Vaughan
Journal:  J Mol Endocrinol       Date:  2007-07       Impact factor: 5.098

Review 10.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

View more
  2 in total

1.  The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review.

Authors:  Yanbo Liu; Yupei Shao; Jiping Xie; Linlin Chen; Guang Zhu
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

Review 2.  Duality of Interactions Between TGF-β and TNF-α During Tumor Formation.

Authors:  Zhi-Wei Liu; Yi-Ming Zhang; Li-Ying Zhang; Ting Zhou; Yang-Yang Li; Gu-Cheng Zhou; Zhi-Ming Miao; Ming Shang; Jin-Peng He; Nan- Ding; Yong-Qi Liu
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.